Citations

Mayo Clinic

Showing 10 of 108602 citations.

Does value-based purchasing affect US hospital utilization pattern: A comparative study
Spaulding, Aaron , Haley, D. Rob , Zhao, Mei , Tafili, Aurora , Zakari, Nazik , Spaulding, Aaron , Haley, Donald Rob , Hamadi, Hanadi

International Journal of Healthcare Management | September 6, 2017 | Volume: 12 | Issue: 2 | Pages: 148-154

10.1080/20479700.2017.1371388 Get It

Targeted next‐generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS‐R
Tefferi, Ayalew , Patnaik, Mrinal M. , Saeed, Lyla, Mudireddy, Mythri , Idossa, Damé , Finke, Christy M. , Ketterling, Rhett P. , Pardanani, Animesh , Gangat, Naseema , Lasho, Terra L. , Patnaik, Mrinal , Mudireddy, Mythri , Ketterling, Rhett P

American Journal of Hematology | September 6, 2017 | Volume: 92 | Issue: 12 | Pages: 1311-1317

10.1002/ajh.24901 | PMID 28875545 Get It

AbstractA 27‐gene panel was used for next‐generation sequencing (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised International Prognostic Scoring System (IPSS‐R) was 11% very high, 18% high, 17% intermediate, 38% low and 16% very low. At least one mutation/variant was detected in 147 (82%) patients; 23% harbored three or more mutations/variants. The most frequent mutations/variants included ASXL1 (30%), TET2 (25%), SF3B1 (20%), U2AF1 (16%), SRSF2 (16%), TP53 (13%), RUNX1 (11%), and DNMT3A (10%). At a median follow up of 30 months, 148 (83%) deaths and 26 (15%) leukemic transformations were recorded. Multivariable analysis of mutations/variants identified ASXL1 (HR 1.7, 95% CI 1.2‐2.5), SETBP1 (HR 4.1, 95% CI 1.6‐10.2) and TP53 (HR 2.2, 95% CI 1.3‐3.4) as risk factors for overall and SRSF2 (HR 3.9, 95% CI 1.5‐10.2), IDH2 (HR 3.7, 95% CI 1.2‐11.4), and CSF3R (HR 6.0, 95% CI 1.6‐22.6) for leukemia‐free survival. Addition of age to the multivariable model did not affect these results while accounting for IPSS‐R weakened the significance of TP53 mutations/variants (P = .1). An apparently favorable survival impact of SF3B1 mutations was no longer evident after adjustment for IPSS‐R. Approximately 41% and 20% of patients harbored at least one adverse mutation/variant for overall and leukemia‐free survival, respectively. Number of mutations/variants did not provide additional prognostic value. The survival impact of adverse mutations was most evident in IPSS‐R very low/low risk patients. These observations suggest that targeted NGS might assist in treatment decision‐making in lower risk MDS.
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Margenthaler, Julie A. , Aft, Rebecca , Gray, Richard J. , Wilke, Lee G. , Haddad, Tufia C. , Moynihan, Timothy J. , Loprinzi, Charles L. , Barnell, Erica K. , Skidmore, Zachary L. , Feng, Yan-Yang, Krysiak, Kilannin , Guo, Zhanfang , Nehring, Leslie, Wisinski, Kari B. , Sanati, Souzan , Al‐Kateb, Hussam , Griffith, Obi L. , Griffith, Malachi , Doyle, L. Austin, Erlichman, Charles , Suman, Vera, Northfelt, Donald, Haddad, Tufia, Moynihan, Timothy, Loprinzi, Charles, Hieken, Tina, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Suman, Vera J. , Goetz, Matthew P. , Burkard, Mark E. , Ademuyiwa, Foluso O. , Naughton, Michael J. , Tevaarwerk, Amyé , Hieken, Tina J. , Hoog, Jeremy , Mardis, Elaine R. , Hagemann, Ian S. , Vij, Kiran R , Ellis, Matthew J.

Clinical Cancer Research | September 5, 2017 | Volume: 23 | Issue: 22 | Pages: 6823-6832

10.1158/1078-0432.ccr-17-1260 | PMID 28874413 Get It

Abstract Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. Experimental Design: Potential eligible patients with clinical stage II/III ER+/HER2− breast cancer were preregistered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing. Patients positive for PIK3CA mutation in the tumor were eligible to start MK-2206 (150 mg orally weekly, with prophylactic prednisone) on cycle 1 day 2 (C1D2) and to receive a maximum of four 28-day cycles of combination therapy before surgery. Serial biopsies were collected at preregistration, C1D1 and C1D17. Results: Fifty-one patients preregistered and 16 of 22 with PIK3CA-mutant tumors received study drug. Three patients went off study due to C1D17 Ki67 >10% (n = 2) and toxicity (n = 1). Thirteen patients completed neoadjuvant therapy followed by surgery. No pCRs were observed. Rash was common. MK-2206 did not further suppress cell proliferation and did not induce apoptosis on C1D17 biopsies. Although AKT phosphorylation was reduced, PRAS40 phosphorylation at C1D17 after MK-2206 persisted. One patient acquired an ESR1 mutation at surgery. Conclusions: MK-2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA-mutant ER+ breast cancer and should not be studied further in the target patient population. Clin Cancer Res; 23(22); 6823–32. ©2017 AACR.
Thalidomide: Rebirth of a Gestational Antiemetic?
Ruddy, Kathryn J. , Navari, Rudolph M. , Loprinzi, Charles L.

Journal of Clinical Oncology | September 5, 2017 | Volume: 35 | Issue: 31 | Pages: 3523-3524

10.1200/jco.2017.74.9663 | PMID 28872926 Get It

Seasonal variation in hospitalization outcomes in patients admitted for heart failure in the United States
Akintoye, Emmanuel , Briasoulis, Αlexandros , Egbe, Alexander C. , Alliu, Samson , Sheikh, Muhammad Adil , Singh, Manmohan , Ahmed, Abdelrahman , Mallikethi‐Reddy, Sagar , Levine, Diane , Briasoulis, Alexandros, Alliu, Samson , Briasoulis, Alexandros , Adegbala, Oluwole Muyiwa

Clinical Cardiology | September 5, 2017 | Volume: 40 | Issue: 11 | Pages: 1105-1111

10.1002/clc.22784 | PMID 28873233 Get It

BackgroundThere is lack of evidence of the impact of varying season on heart failure (HF) hospitalization outcomes in the U.S.HypothesisHF hospitalization outcomes exhibit significant seasonal variation in the U.S.MethodsUsing data from the National Inpatient Sample (2011‐2013), seasonal variation was classified based on meteorological classification of Northern Hemisphere–Spring, Summer, Fall, & Winter–and analysis was conducted via multivariable‐adjusted mixed‐effect model.ResultsAn estimated 2.8 million adults were hospitalized for HF in the U.S. from 2011 to 2013. Of all hospitalizations, admissions were highest in Winter (27%), followed by Spring (26%), Fall (24%), and Summer (23%). The overall mortality rate was 3.1%. Compared with Spring, there was significantly lower mortality in Summer (odds ratio [OR]: 0.95, 95% CI: 0.91‐0.99) and Fall (OR: 0.94, 95% CI: 0.89‐0.98), but the highest mortality was in Winter (OR: 1.06, 95% CI: 1.02‐1.11). In addition, mean length of stay and median cost of hospitalization were highest in Winter (5.3 days, USD7459, respectively) and lowest in Summer (5.1 days, USD7181, respectively). However, age and sex differences existed (e.g. seasonal variation in inpatient mortality was only significant for patients age ≥65 years, and, comparedwith the Spring season, males had higher risk of inpatient mortality in Winter (OR: 1.10, 95% CI: 1.04‐1.17) and females had lower risk of inpatient mortality in Summer (OR: 0.94, 95% CI: 0.88‐1.00) and Fall (OR: 0.92, 95% CI: 0.87‐0.98).ConclusionsAmong HF patients in the U.S., hospitalization outcomes were worse in Winter but better in Summer.
Inaccuracies Describing Results of a Lung Cancer Screening Demonstration Project
Humphrey, Linda L., Deffebach, Mark, Midthun, David E.

JAMA Internal Medicine | September 5, 2017 | Volume: 177 | Issue: 9 | Pages: 1396

10.1001/jamainternmed.2017.3120 | PMID 28873187 Get It

Smartphone photography utilized to measure wrist range of motion
Wagner, Eric R. , Mica, Megan Conti , Wagner, Eric R , Shin, Alexander Y.

Journal of Hand Surgery (European Volume) | September 5, 2017 | Volume: 43 | Issue: 2 | Pages: 187-192

10.1177/1753193417729140 | PMID 28872411 Get It

The purpose was to determine if smartphone photography is a reliable tool in measuring wrist movement. Smartphones were used to take digital photos of both wrists in 32 normal participants (64 wrists) at extremes of wrist motion. The smartphone measurements were compared with clinical goniometry measurements. There was a very high correlation between the clinical goniometry and smartphone measurements, as the concordance coefficients were high for radial deviation, ulnar deviation, wrist extension and wrist flexion. The Pearson coefficients also demonstrated the high precision of the smartphone measurements. The Bland–Altman plots demonstrated 29–31 of 32 smartphone measurements were within the 95% confidence interval of the clinical measurements for all positions of the wrists. There was high reliability between the photography taken by the volunteer and researcher, as well as high inter-observer reliability. Smartphone digital photography is a reliable and accurate tool for measuring wrist range of motion. Level of evidence: II
Silicone Oil–Induced Nasal Polyposis: A Case Report
Patel, Vishal S. , Hwang, Peter H. , Kossler, Andrea L. , Choby, Garret

Otolaryngology–Head and Neck Surgery | September 5, 2017 | Volume: 157 | Issue: 5 | Pages: 903-904

10.1177/0194599817728896 | PMID 28871877 Get It